RF 360

Hatch-Waxman Litigation

Tenacious. Trusted. Talented.

Rothwell Figg is known for our pharmaceutical litigation practice, having represented pharmaceutical companies in more than 40 litigations arising out of the Drug Price Competition and Patent Term Restoration Act (the “Hatch-Waxman amendments”). Trial and appellate litigation under the Hatch-Waxman amendments forms a significant part of the firm’s litigation practice, with several of our partners devoting nearly all of their time to pharmaceutical litigation, representing both brand-name pharmaceutical innovators and generic drug manufacturers.  Over the years we have invalidated dozens of pharmaceutical patents, and have successfully pursued antitrust cases arising out of the improper listing of patents in the Orange Book, culminating in settlements of over $500 million from such claims.